CymaBay Therapeutics (CBAY) Tops Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CBAY Hot Sheet
Join SI Premium – FREE
CymaBay Therapeutics (NASDAQ: CBAY) reported Q2 EPS of ($0.01), $0.19 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $31 million versus the consensus estimate of $11.38 million.
For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- IndeRes Upgrades Nokia OYJ (NOKIA:FH) (NOK) to Reduce (3)
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
